WebbPatients received T-DM1 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of ... exploratory analysis of patients with HER2-positive metastatic … Webb5 dec. 2024 · e e ea ura o ee n engl j med 380;7 nejm.orgFebruary 14, 2024 617 established in 1812 February 14, 2024 vol. 380 no. 7 The authors’ full names, academic …
Adjuvant trastuzumab emtansine in HER2-positive breast cancer …
Webb11 juni 2024 · In this patient population, T-DM1 (trastuzumab emtansine), the first ADC to be developed for solid tumors has long cemented itself as the standard of care for second-line treatment of metastatic HER2+ breast cancer.T-DM1 combines the anti-HER2 mAb, trastuzumab, with the potent microtubule inhibitor, DM1 via a stable, thioether linker. WebbIn the KATHERINE study, T-DM1 demonstrated increased efficacy compared to trastuzumab in Chinese patients. Consistent with previous data in Asian patients, T … camouflage golf towel
Long-term outcomes of patients with HER2+ breast cancer with …
Webbneoadjuvant therapies who can benefit by switching to T-DM1.” T-DM1 is currently approved by the U.S. Food and Drug Administration to treat patients with metastatic HER2-positive breast cancer following previous treatment with trastuzumab and a taxane type of chemotherapy. KATHERINE is an open-label study of 1,486 patients with HER2 … Webb14 feb. 2024 · Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and … Webb25 mars 2024 · Relying on the positive results in metastatic setting, T-DM1 was tested as adjuvant therapy in patients with residual invasive disease after neoadjuvant chemotherapy for HER2-positive BC. The practice-changing KATHERINE trial showed that adjuvant T-DM1 halved the risk of recurrences in comparison to adjuvant trastuzumab . first script network services coventry